Incidence, severity, and outcomes of AKI associated with dual renin-angiotensin system blockade

Clinical Journal of the American Society of Nephrology

Volumn 11, Issue 11, 2016, Pages 1944-1953

  Palevsky, Paul M ^a,b   Zhang, Jane H ^c   Seliger, Stephen L ^a,d   Emanuele, Nicholas ^a,e   Fried, Linda F ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

acute kidney injury; Albumins; Ambulatory Care; angiotensin converting enzyme inhibitor; angiotensin receptor blocker; Arm; chronic kidney disease; creatinine; diabetes mellitus; Diabetes Mellitus, Type 2; diabetic nephropathy; Follow Up Studies; glomerular filtration rate; Humans; Incidence; Kidney Failure, Chronic; Lisinopril; Losartan; Nephrons; proteinuria; renin angiotensin system; Renin Angiotensin System; risk factors; Veterans

Indexed keywords

LISINOPRIL; LOSARTAN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSTRUCTIVE UROPATHY; OUTPATIENT CARE; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; AGED; ALBUMINURIA; BLOOD PRESSURE; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; COMBINATION DRUG THERAPY; CONVALESCENCE; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; HEART FAILURE; INCIDENCE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY;

ACUTE KIDNEY INJURY; AGED; ALBUMINURIA; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; LISINOPRIL; LOSARTAN; MALE; MIDDLE AGED; RECOVERY OF FUNCTION; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 85021750625     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03470316     Document Type: Article

References (29)

1. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 65: 2309–2320, 2004
2. Kidney Disease: Improving Global Outcomes (KDIGO) Work Group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3: 1–150, 2013
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. NEngl J Med 329: 1456–1462, 1993
4. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851–860, 2001
5. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861–869, 2001
6. de Zeeuw D: Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int Suppl 92: S2-S6, 2004
7. Kunz R, Friedrich C, Wolbers M, Mann JF: Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148: 30–48, 2008
8. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group: Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359: 1225–1237, 2008
9. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C; ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547–1559, 2008
10. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O’Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P; VA NEPHRON-D Investigators: Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369: 1892–1903, 2013
11. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators: Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367: 2204–2213, 2012
12. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 372: 547–553, 2008
13. Fried LF, Duckworth W, Zhang JH, O’Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P; VA NEPHRON-D Investigators: Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 4: 361–368, 2009
14. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247–254, 2006
15. Badr KF, Ichikawa I: Prerenal failure: A deleterious shift from renal compensation to decompensation. NEngl J Med319: 623–629, 1988
16. Schnermann J, Briggs JP, Weber PC: Tubuloglomerular feedback, prostaglandins, and angiotensin in the autoregulation of glomerular filtration rate. Kidney Int 25: 53–64, 1984
17. Munger KA, Kost CK Jr., Brenner BM, Maddox DA: The renal circulations and glomerular ultrafiltration. In: Brenner & Rector’s The Kidney, 9th Ed., edited by Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu ASL, Brenner BM, Philadelphia, Elsevier Saunders, 2012, pp 94–137
18. Taal MW, Brenner BM: Adaption to nephron loss and mechanisms of progression in chronic kidney disease. In: Brenner & Rector’s The Kidney, 9th Ed., edited by Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu ASL, Brenner BM, Philadelphia, Elsevier Saunders, 2012, pp 1918–1971
19. Abuelo JG: Normotensive ischemic acute renal failure. N Engl J Med 357: 797–805, 2007
20. Ruggenenti P, Remuzzi G: RAS blockade: Nephroprotection by dual RAS blockade–a welcome back. Nat Rev Nephrol 11: 507– 508, 2015
21. Heerspink HJ, Kröpelin TF, Hoekman J, de Zeeuw D; Reducing Albuminuria as Surrogate Endpoint (REASSURE) Consortium: Drug-induced reduction in albuminuria is associated with subsequent renoprotection: A meta-analysis. J Am Soc Nephrol 26: 2055–2064, 2015
22. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321: 1440–1444, 2000
23. Rossing K, Christensen PK, Jensen BR, Parving HH: Dual blockade of the renin-angiotensin system in diabetic nephropathy: A randomized double-blind crossover study. Diabetes Care 25: 95–100, 2002
24. Rossing K, Jacobsen P, Pietraszek L, Parving HH: Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: A randomized double-blind crossover trial. Diabetes Care 26: 2268–2274, 2003
25. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD: Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 20: 2641–2650, 2009
26. Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, Wiebe N, Ruospo M, Wheeler DC, Strippoli GF: Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: A network meta-analysis. Lancet 385: 2047–2056, 2015
27. Yacoub R, Patel N, Lohr JW, Rajagopalan S, Nader N, Arora P: Acute kidney injury and death associated with renin angiotensin system blockade in cardiothoracic surgery: A meta-analysis of observational studies. Am J Kidney Dis 62: 1077–1086, 2013
28. Coca SG, Garg AX, Swaminathan M, Garwood S, Hong K, Thiessen-Philbrook H, Passik C, Koyner JL, Parikh CR; TRIBE-AKI Consortium: Preoperative angiotensin-converting enzyme inhibitors and angiotensin receptor blocker use and acute kidney injury in patients undergoing cardiac surgery. Nephrol Dial Transplant 28: 2787–2799, 2013
29. Testani JM, Kimmel SE, Dries DL, Coca SG: Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 4: 685–691, 2011